Back to today’s briefing

Story perspectives

Akari Therapeutics' PH1: A New Frontier in Cancer Treatment

7/26/2025

32 4

Summary

Story summary

Akari Therapeutics is making strides in cancer research with PH1, a powerful spliceosome modulator in its antibody drug conjugates. This innovative treatment not only triggers cancer cell death but also sparks immune responses by creating neoantigens. With further studies underway, the company anticipates revealing preliminary data on PH1's impact on critical oncogenic drivers by the end of the year.

1 of 1

Story summary

Akari Therapeutics is making strides in cancer research with PH1, a powerful spliceosome modulator in its antibody drug conjugates. This innovative treatment not only triggers cancer cell death but also sparks immune responses by creating neoantigens. With further studies underway, the company anticipates revealing preliminary data on PH1's impact on critical oncogenic drivers by the end of the year.